Welcome to our dedicated page for Sotera Health Co news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Co stock.
Sotera Health Company (NASDAQ: SHC) is described as a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Through its Sterigenics, Nordion and Nelson Labs businesses, the company focuses on sterilization, analytical testing and related services that support the safety of medical, pharmaceutical and food products.
The SHC news feed on Stock Titan highlights company announcements that matter to investors and observers of the healthcare services and testing laboratories space. These include quarterly and year-to-date financial results, updates on revenue trends and segment performance for Sterigenics, Nordion and Nelson Labs, as well as information on leverage, credit facilities and other balance sheet items described in press releases and Form 8-K filings.
Users can also follow news about secondary offerings of common stock by selling stockholders, as disclosed in company press releases and related 8-K filings. These items explain when affiliates of investment firms have sold blocks of SHC shares and clarify that Sotera Health did not receive proceeds from those transactions.
Regulatory and legal developments are another important category of news for Sotera Health. Public disclosures describe litigation and settlements related to ethylene oxide emissions at certain Sterigenics facilities, along with broader risk discussions around EO, Co-60 supply, regulatory changes and international operations. Conference participation, earnings release dates and management presentations at healthcare investor events are also covered in the company’s news flow.
By reviewing this news stream, readers can see how Sotera Health communicates its financial performance, capital markets activity, legal developments and strategic positioning in sterilization and lab testing services over time.
Sterigenics S.A.S., a Sotera Health subsidiary, is expanding its ethylene oxide sterilization facility in Rantigny, France, to enhance sterilization capacity and capability. This expansion addresses increased local and regional demand for contract sterilization services in the healthcare sector. The facility will now include a 32-pallet chamber, improving throughput and flexibility for customers. This development follows Sterigenics' recent acquisition of Iotron Industries, further diversifying sterilization technologies and enhancing global service offerings.
Sotera Health Company (Nasdaq: SHC) reported Q4 2020 net revenues of $217 million, a 12% increase year-over-year. However, the Q4 net loss was $44 million, up from a $28 million loss in Q4 2019, factoring in significant debt extinguishment costs. Adjusted EBITDA rose 20% to $113 million, and Adjusted EPS improved to $0.09. For 2021, Sotera projects revenues of $890 million to $920 million (growth of 9% to 12%) and Adjusted EBITDA of $465 million to $485 million (growth of 11% to 16%).
Sotera Health Company (Nasdaq: SHC) announced that its CFO, Scott Leffler, will present at the Citi 2021 Healthcare Services Conference on February 24, 2021, at 8:00 am ET. Additionally, CEO Michael B. Petras, Jr. will present at the Barclays Global Healthcare Conference on March 10, 2021, at 9:10 am ET. Investors can access both live and archived webcasts via the Sotera Health website. Sotera Health specializes in end-to-end sterilization solutions and lab testing services and is committed to its mission of Safeguarding Global Health.
Sotera Health Company (Nasdaq: SHC) announced the successful amendment and repricing of its First Lien Term Loan, reducing the interest rate spread from 450 to 275 basis points and the LIBOR floor from 100 to 50 basis points. This results in a 2.25% decrease in effective interest rates, leading to expected annual cash interest savings of approximately $40 million. The repricing aims to improve liquidity and support strategic investments, despite potential offsetting charges from the amendment.
Sotera Health Company (Nasdaq: SHC) announced preliminary results for the fourth quarter and full year 2020, expecting revenues of approximately $216 million and $817 million respectively, reflecting an annual growth rate of 5%. The company highlighted its strategic acquisition, capacity investments, and successful IPO as pivotal moves during a challenging pandemic year. Pro forma revenue estimates suggest a full-year total of $832 million when accounting for pre-acquisition contributions. The company is scheduled to present at the J.P. Morgan Healthcare Conference today and will release detailed earnings on March 9, 2021.
Sotera Health Company (Nasdaq: SHC) announced significant debt reduction, paying off over $1.1 billion following its recent IPO. The company redeemed $770 million in senior secured notes and reduced its first lien term loan by $341 million. Additionally, Sotera Health increased its revolving credit facility from $190 million to $347.5 million, which remains undrawn. This strategic move aims to enhance capital structure and liquidity, facilitating growth and further de-leveraging. As of September 30, 2020, its net leverage ratio stands at approximately 4.5x.
Sotera Health Company (Nasdaq: SHC) will be represented by Chairman and CEO Michael B. Petras, Jr. at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 7:30 am ET. This leading global provider focuses on end-to-end sterilization solutions and lab testing services for healthcare. Interested investors can access the live and archived webcast via Sotera Health's Investor Relations page.
Sotera Health operates through three divisions: Sterigenics®, Nordion®, and Nelson Labs®, with a commitment to Safeguarding Global Health®.
Sotera Health Company (Nasdaq: SHC) has successfully closed its initial public offering (IPO) of 53,590,000 shares at $23.00 each, generating approximately $1.2 billion in gross proceeds. The offering involved prominent financial institutions: J.P. Morgan, Credit Suisse, Goldman Sachs & Co. LLC, and Jefferies, among others. The registration statement was declared effective on November 19, 2020, by the SEC. Sotera Health focuses on end-to-end sterilization solutions and lab testing services for healthcare, committed to its mission of Safeguarding Global Health®.
Sotera Health Company has priced its initial public offering (IPO) of 46,600,000 shares at $23.00 each, aiming for gross proceeds of approximately $1.1 billion. The shares will begin trading on the Nasdaq under the symbol 'SHC' on November 20, 2020, and the offering is expected to close on November 24, 2020. Underwriters include J.P. Morgan, Credit Suisse, Goldman Sachs, and Jefferies, with an option for up to 6,990,000 additional shares. The registration statement was effective as of November 19, 2020, and the offering will be governed by a prospectus.